Bourne Partners considers home and alternate site infusion therapy as one of the most attractive verticals in healthcare services today based on primary and secondary research that it has completed in recent months. In Bourne Partners’ view, the home and alternate site infusion therapy marketplace has become increasingly fragmented with the sudden decision by CVS Health (NYSE-CVS) to exit the space last year. As such, Bourne Partners sees significant opportunities for consolidation in the coming years.
Read the full article: Market Insight: Home and Alternate Site Infusion Therapy Marketplace //
Source: https://bourne-partners.com/sector-report/market-insight-home-and-alternate-site-infusion-therapy-marketplace/